@misc{peter_tacrolimusresistant_sarscov2specific_2022, 
author={Peter, L., Wendering, D.J., Schlickeiser, S., Hoffmann, H., Noster, R., Wagner, D.L., Zarrinrad, G., Münch, S., Picht, S., Schulenberg, S., Moradian, H., Mashreghi, M.-F., Klein, O., Gossen, M., Roch, T., Babel, N., Reinke, P., Volk, H.-D., Amini, L., Schmueck-Henneresse, M.},
title={Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients},
year={2022},
howpublished = {journal article},
doi = {https://doi.org/10.1016/j.omtm.2022.02.012},
abstract = {Solid organ transplant (SOT) recipients receive therapeutic immunosuppression that compromises their immune response to infections and vaccines. For this reason, SOT patients have a high risk of developing severe coronavirus disease 2019 (COVID-19) and an increased risk of death from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Moreover, the efficiency of immunotherapies and vaccines is reduced due to the constant immunosuppression in this patient group. Here, we propose adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, tacrolimus, for optimized performance in the immunosuppressed patient. Using a ribonucleoprotein approach of CRISPR-Cas9 technology, we have generated tacrolimus-resistant SARS-CoV-2-specific T cell products from convalescent donors and demonstrate their specificity and function through characterizations at the single-cell level, including flow cytometry, single-cell RNA (scRNA) Cellular Indexing of Transcriptomes and Epitopes (CITE), and T cell receptor (TCR) sequencing analyses. Based on the promising results, we aim for clinical validation of this approach in transplant recipients. Additionally, we propose a combinatory approach with tacrolimus, to prevent an overshooting immune response manifested as bystander T cell activation in the setting of severe COVID-19 immunopathology, and tacrolimus-resistant SARS-CoV-2-specific T cell products, allowing for efficient clearance of viral infection. Our strategy has the potential to prevent severe COVID-19 courses in SOT or autoimmunity settings and to prevent immunopathology while providing viral clearance in severe non-transplant COVID-19 cases.},
note = {Online available at: \url{https://doi.org/10.1016/j.omtm.2022.02.012} (DOI). Peter, L.; Wendering, D.; Schlickeiser, S.; Hoffmann, H.; Noster, R.; Wagner, D.; Zarrinrad, G.; Münch, S.; Picht, S.; Schulenberg, S.; Moradian, H.; Mashreghi, M.; Klein, O.; Gossen, M.; Roch, T.; Babel, N.; Reinke, P.; Volk, H.; Amini, L.; Schmueck-Henneresse, M.: Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Molecular Therapy. Methods & Clinical Development. 2022. vol. 25, 52-73. DOI: 10.1016/j.omtm.2022.02.012}}